A Targetable EGFR-Dependent Tumor-Initiating Program in Breast Cancer

A Targetable EGFR-Dependent Tumor-Initiating Program in Breast Cancer

Summary: Therapies targeting epidermal growth factor receptor (EGFR) have variable and unpredictable responses in breast cancer. Screening triple-negative breast cancer (TNBC) patient-derived xenografts (PDXs), we identify a subset responsive to EGFR inhibition by gefitinib, which displays heterogen...

Full description

Bibliographic Details
Main Authors: Paul Savage, Alexis Blanchet-Cohen, Timothée Revil, Dunarel Badescu, Sadiq M.I. Saleh, Yu-Chang Wang, Dongmei Zuo, Leah Liu, Nicholas R. Bertos, Valentina Munoz-Ramos, Mark Basik, Kevin Petrecca, Jamil Asselah, Sarkis Meterissian, Marie-Christine Guiot, Atilla Omeroglu, Claudia L. Kleinman, Morag Park, Jiannis Ragoussis
Format: Article
Language:English
Published: Elsevier 2017-10-01
Series:Cell Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S221112471731447X

Internet

http://www.sciencedirect.com/science/article/pii/S221112471731447X

Similar Items